- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Aequus and Ehave Collaborate on Bioinformatics Platform
Aequus Pharmaceuticals announced it entered a new collaboration with Ehave.
Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced it entered a new collaboration with Ehave (OTCQB:EHVVF) whereby Aequus will gain access to Ehave’s bioinformatics platform for use in their upcoming clinical trials for its portfolio products.
As quoted in the press release:
The two companies plan to collaborate on conducting trials in both the traditional pharmaceutical drug regulatory regime and in the medical cannabis regulatory regime. Aequus will pay Ehave a per-patient fee for trials conducted using the Ehave bioinformatics platform and will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profiles content from formal and informal studies conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results and data generated from trials using the Ehave platform.
“We are excited to work with Ehave as we advance various development programs, both our traditional pharmaceutical products and medical cannabinoid containing products, through clinical trials,” says Doug Janzen, Chairman and CEO of Aequus.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.